Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma

Volume: 12, Issue: 1, Pages: 1 - 10
Published: Feb 1, 2017
Abstract
Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted...
Paper Details
Title
Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Published Date
Feb 1, 2017
Volume
12
Issue
1
Pages
1 - 10
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.